Figure 2.
Impact of SIRPα mismatch on cGVHD. Cumulative incidence of overall cGVHD (A), de novo cGVHD (B), overall cGVHD requiring systemic therapy (C), and de novo cGVHD requiring systemic therapy (D) according to SIRPα variant matching status.
Impact of SIRPα mismatch on cGVHD. Cumulative incidence of overall cGVHD (A), de novo cGVHD (B), overall cGVHD requiring systemic therapy (C), and de novo cGVHD requiring systemic therapy (D) according to SIRPα variant matching status.